Fulcrum Therapeutics filed the paperwork for there IPO to raise up to $86 million on 6/21/19. The company has three small molecule candidates in development that aim to treat the root cause of a genetically defined rare disease. Fulcrum intends to trade on NASDAQ under the symbol “FULC.”
Fulcrum has three candidates in development and four in the discovery stage. Its lead candidate, losmapimod, is being developed to treat Facioscapulohumeral muscular dystrophy (FSHD). FSHD is a rare, progressive and disabling disease for which there are no approved treatments. The company intends to initiate Ph IIb trials in mid 2019. The company's other candidates in clinical development include one for beta-thalassemia and one for sickle cell disease.
Fulcrum announced an $80 million series B round in September of 2018. At the time of the announcement the company said it intended to use the funds to advance development of losmapimod.